Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (98)

« Back to Publications

Developing a global framework to assess a country's readiness and resilience to introduce a new vaccine or improve uptake of an underutilized vaccine.

Monk V. et al, (2026), Expert Rev Vaccines, 25

Parental motivations, facilitators, and barriers to participating in a pediatric vaccine trial in Kathmandu, Nepal: A qualitative study.

Firth C. et al, (2026), Hum Vaccin Immunother, 22

What is unhealthy about public health? Vaccination, evidence and the politics of uncertainty

Mezza M. and Vanderslott S., (2026), Humanities and Social Sciences Communications, 13

The impact of the COVID-19 pandemic on healthy volunteer motivations: a mixed-methods study of participants in plague vaccine trials in the UK and Uganda.

Stuart AS. et al, (2026), BMC Public Health

En-risk to de-risk: An iterative human factors framework for scale development in emerging technologies.

Kantor J. et al, (2026), JAAD Int, 24, 342 - 345

Public attitudes towards intranasal and ultrasound mediated vaccine delivery: A cross-sectional study in the United Kingdom and United States.

Kantor J. et al, (2026), Vaccine, 69

Afterword

Vanderslott S., (2026), 167 - 171

Early lymph node T follicular helper cell signalling hub drives influenza vaccine response in an ancestrally diverse cohort.

Siu JHY. et al, (2025), EBioMedicine, 122

Development and validation of the Oxford Benchmark Scale for Rating Vaccine Technologies (OBSRVT), a scale for assessing public attitudes to next-generation vaccine delivery technologies.

Kantor J. et al, (2025), Hum Vaccin Immunother, 21

Discriminative Cut-Offs, Concurrent Criterion Validity, and Test-Retest Reliability of the Oxford Vaccine Hesitancy Scale.

Kantor J. et al, (2025), Vaccines (Basel), 13

WHO pandemic agreement.

Norton A. et al, (2025), BMJ, 390

A systematic review on patient and public attitudes toward health monitoring technologies across countries.

Chen T. et al, (2025), NPJ Digit Med, 8

Acceptability of the gonorrhoea human challenge model to accelerate vaccine development in UK men.

Firth C. et al, (2025), Vaccine, 54

Confronting the shortcomings of covid-19 vaccination will help us in future pandemics.

Vanderslott S., (2025), BMJ, 388

Artificial intelligence for modelling infectious disease epidemics.

Kraemer MUG. et al, (2025), Nature, 638, 623 - 635

Load More

1
2
3
4
5
6
7